ARCHIVES

Revlimid Extends Time To Progression Compared To Placebo In Phase III Trial

This article is from The Cancer Letter archive.

Vol. 32 No. 12 | December 25, 2009

Download PDF Visit The Full Archive

Related Articles

ACCC Manual Tells How To Set Up, Run Cancer Program

August 27, 1976

Pediatric Rule Makes FDA Consider Defining Tumors By Molecular Target.

August 31, 2001

Review Of NCI Intramural Program Offers Over 60 Recommendations For Change

July 7, 1995

DCE Board Approves Recompetition Of Large Support Contracts

March 16, 1990

Weicker Ready To Fight for Increased NCI, NIH Funding, Objects to Limits On Grants, Positions

March 14, 1986

In Brief: Senate Committee Cuts House Amount For NCI; NCI Staff Faces Up to 22 Days Unpaid Leave

September 21, 1990